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Background: Supervised injection facilities (SIFs) are venues where people who inject drugs (PWID) have access to
a clean and medically supervised environment in which they can safely inject their own illicit drugs. There is
currently only one legal SIF in North America: Insite in Vancouver, British Columbia, Canada. The responses and
feedback generated by the evaluations of Insite in Vancouver have been overwhelmingly positive. This study
assesses whether the above mentioned facility in the Downtown Eastside of Vancouver needs to be expanded to
other locations, more specifically that of Canada’s capital city, Ottawa.
Methods: The current study is aimed at contributing to the existing literature on health policy by conducting
cost-benefit and cost-effective analyses for the opening of SIFs in Ottawa, Ontario. In particular, the costs of
operating numerous SIFs in Ottawa was compared to the savings incurred; this was done after accounting for the
prevention of new HIV and Hepatitis C (HCV) infections. To ensure accuracy, two distinct mathematical models and
a sensitivity analysis were employed.
Results: The sensitivity analyses conducted with the models reveals the potential for SIFs in Ottawa to be a fiscally
responsible harm reduction strategy for the prevention of HCV cases – when considered independently. With a
baseline sharing rate of 19%, the cumulative annual cost model supported the establishment of two SIFs and the
marginal annual cost model supported the establishment of a single SIF. More often, the prevention of HIV or HCV
alone were not sufficient to justify the establishment cost-effectiveness; rather, only when both HIV and HCV are
considered does sufficient economic support became apparent.
Conclusions: Funded supervised injection facilities in Ottawa appear to be an efficient and effective use of financial
resources in the public health domain.
Keywords: Supervised injection facilities, HIV, HCVBackground
The spread of infectious diseases among people who inject
drugs (PWID) is a major public health issue. Research
studies conducted throughout the developed and de-
veloping world have found that diseases such as human
immunodeficiency virus/acquired immunodeficiency
syndrome (HIV/AIDS) and hepatitis C virus (HCV) are
some of the leading causes of death among PWID who
share needles and engage in other unsafe practices [1].
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unless otherwise stated.are approximately 16 million people who inject drugs
worldwide, and 3 million of those PWID are suffering
from HIV [2]. The most recent data in Canada indi-
cates that in the year 2002, there were almost 1700
deaths related to illegal drug use. Moreover, that year,
there were 87 AIDS deaths caused by illegal drug use
and it was found that 70 percent of the new HCV in-
fections could be traced to illegal drug use [3]. In an
effort to control this public health issue, needle ex-
change programmes (NEP) have become one of the
most established means of harm reduction among
PWID and have proven to have a positive impact on
public health [2-7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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address this public health issue – is the supervised injec-
tion facility (SIF). SIFs are venues where people who inject
drugs have access to a clean and medically supervised en-
vironment in which they can safely inject their own illicit
drugs. There is currently only one legal SIF in North
America – Insite in Vancouver, British Columbia, Canada.
Since beginning its operations in 2003, this facility has
been examined in over 50 peer-reviewed studies. The vast
majority of these studies have had positive conclusions.
For example, there has been a reduction in overdose fatal-
ities, needle sharing, and an improvement in public order
[8-13]. Many of these studies’ analyses have shown Insite
to be cost-effective: saving taxpayers considerable money
through the prevention of new HIV and HCV infections
as well as reducing risky injection behaviours [8,14-17].
Given these facts, it has been proposed that the use of SIFs
should be expanded to other large cities in Canada, such
as Victoria, Montreal and Ottawa [14,18,19].
A report published in 2004 citing personal communica-
tion with Professor Robert Remis, stated that the PWID
population in Ottawa, Ontario comprised between 3,000
and 5,000 individuals [20]. Ottawa’s PWID population cur-
rently has some of the highest rates of new HIV and HCV
infections [21]. Studies have estimated HIV prevalence
ranging from 11% to 21% and HCV prevalence between
55% and 76% [21,22]. These rates are both higher than
those found in Toronto, which is Canada’s largest city with
a population of over 6 million persons residing in the
Greater Toronto Area [21]. Leonard et al. found that
among Ottawa PWID, 37% of women and 31% of men
said they injected with used needles in the six months pre-
ceding their interview with the researchers [22]. More
troubling is the fact that the rates of infection and unsafe
injection practices are so high despite the widespread use
of NEPs and other harm reduction strategies.
Given this data, it can be argued that new strategies
should be considered to help reduce these rates and pre-
vent new infections from occurring in PWID. In effect,
The Sandy Hill Community Health Centre and partners
planned to submit an exemption application for many
years but it has been delayed because both Mayor Jim
Watson and police Chief Charles Bordeleau have opposed
the idea. Dr. Mark Tyndall, chief of infectious diseases at
the Ottawa Hospital, told an audience at a recent rally at
the Canadian Parliament hill that “a site would send a
message of care to addicts and reduce harm. Tyndall said
many drug users in Ottawa aren’t accessing existing
services, and says a site would connect them” [23], p. 1.
Moreover, a group of community members that advocate
for the opening of safer consumption sites in Ottawa for
PWID has been formed and they opine that “the most ef-
fective response to problematic drug use includes harm
reduction, expanded social and health care services,preventative measures to address communicable diseases,
and evidence-based drug policies” [24], p.1.
Furthermore, a team of University of Toronto re-
searchers concluded in a recent report that three SIFs in
Toronto and two SIFs in Ottawa would prevent the
spread of HCV and HIV, save money, and reduce sharing
of needles within the PWID population [21]. However,
the difference between this costing study and Bayoumi
and Strike’s [21] study is the mathematical model and
sensitivity analysis used. Bayoumi and Strike’s [21] study,
similar to Bayoumi and Zaric’s [15], used a complex dy-
namic compartmental simulation model, that incorpo-
rated factors like co-infections, smoking related drug
use, and the proportion receiving methadone. In terms
of HCV, their analysis of Toronto accounted for 15 to 20
preventive cases, thereby resulting in savings of a total
of CAN $47,489 for the first facility [21]. In Ottawa, the
savings are more modest for HCV, predicting a cost-
savings of $18,591 [21].
Along the lines of the Bayoumi and Strike [21] report,
this paper examines if opening SIFs in Ottawa would be
an effective use of fiscal resources – based on the com-
bined cost-savings of co-morbidity infections such as
HIV and HCV. Though recent studies have shown that
the establishment of SIFs is cost-effective, particularly in
a Canadian context [8,14-18,21], it is important to con-
sider the different base rates of HIV and HCV infection,
as well as other model parameters such as needle sharing
rates, that are likely to impact whether SIFs are cost-
effective or not. This is of importance because the specific
PWID characteristics are different in different areas. As a
result of this, different base rates of both HIV and HCV
infections are likely to determine whether SIFs are cost
effective, as shown in the studies listed above. Specific-
ally, this is done by conducting cost-benefit and cost-
effectiveness analyses for operating a SIF in the Ottawa
region. The costs of operating a SIF in Ottawa will be
compared to the savings incurred by the healthcare sys-
tem after accounting for the prevention of new HIV and
HCV infections.
Related research
Closely related to this study is a burgeoning body of re-
cent research that has evaluated the economic viability
of Vancouver’s Insite facility. Much of this research has
investigated the impact of the SIF in reducing the num-
ber of HIV and HCV infections. However, it should be
noted that such a relationship has not been demon-
strated in any definitive manner in the scientific research
conducted. As discussed below, mathematical modelling
approaches are used to estimate expected outcomes, and
not to count actual changes. This lack of definitive scien-
tific evidence is in part due to the same size constraints,
the very high incidence rate of HCV among PWID, and
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Though this is not scientific evidence, these models serve
as excellent tools to identify what kind of changes we can
expect when public health policy is implemented.
The first of these studies was published in 2008. In that
study, Bayoumi and Zaric [15] projected new HIV and
HCV infections for the City of Vancouver over a 10-year
period. Using a complex dynamic compartmental simula-
tion model, the study made projections with and without
the Insite facility. Results estimated that over the 10-year
time period, 1191 new HIV and 54 new HCV cases would
be averted with the implementation and use of the SIF
[15]. As a result, considering the average annual number
of new HIV cases averted (120), the lifetime cost of a new
HIV infection (CDN$210 555) [16,25], and the cost of op-
erations for the SIF portion of Insite (CDN $1.5 million)
[18], the SIF would yield annual savings of CDN $25
million – at a benefit-cost ratio of 16.84.
It has been argued that a more realistic economic as-
sessment was completed by Des Jarlais et al. [26] where
Insite was estimated to prevent 20 – 30 new cases of
HIV each year [14]. Using that figure along with the
same lifetime cost of a new HIV infection (CDN $210
555) and operational cost of Insite (CDN $1.5 million), it
was estimated that benefit-cost ratios varied from 2.81
and 4.21 [26]. These, more conservative estimates, are
not nearly as compelling as those found by Bayoumi and
Zaric [15] but nevertheless sustain sufficient support for
the continued operation of Insite in the City of Vancouver.
Adopting a different methodological approach, Andresen
and Boyd [8] conducted cost-benefit and cost-effectiveness
analyses of Insite that used four separate mathematical
models to assess the economic impact of preventing new
HIV infections each year. Results of their study revealed
that between 19 and 57 new cases may be averted depend-
ing on the model selected, in addition to an average of 35
new cases being prevented every year [8]. With respect to
the benefit-cost analysis, results were comparable to those
of Des Jarlais et al. [26], who considered credible changes
in HIV infection rates, with ratios ranging from 1.94 to 5.8
and an average of 3.56. While these results too, support
the economic rationale for the operation of Insite, more
recent studies have revealed conflicting results.
Pinkerton [16,17], for example, used Kaplan’s [5,27]
needle circulation theory to demonstrate that while
Insite – as a whole – may be very cost-effective, much
of its effectiveness is attributable to its needle exchange
program. In fact, Pinkerton [16,17] concluded that the
SIF component alone does very little to prevent new
cases of HIV. Specifically, of the 83.5 new HIV cases
averted each year in the 2010 study, only 2.8 may be at-
tributed to the SIF [16]. Similarly, the 2011 study revealed
that a mere 4 to 8 new HIV cases are averted each year
[17]. With greatly reduced benefit-cost ratios of 0.37 [16]and 0.8 [17], respectively, these results suggest that the SIF
portion of Insite is not a practical harm reduction option,
at least in economic terms.
While one may question the discrepancy in results be-
tween this collection of studies, Andresen and Jozaghi [14]
note that the differences are attributable to the choices of
variables in the models presented. As such, “Pinkerton
(2010, 2011) does not consider behavioural changes of
PWID with regard to needle-sharing in his models” [14],
p4 while the Bayoumi and Zaric [15] and Andresen and
Boyd [8] studies do. Because previous research has shown
that Insite users have a lower rate of needle-sharing than
non-Insite users [12], the Bayoumi and Zaric [15] and the
Andresen and Boyd [8] approaches should be considered
as more accurate representations of actual change in
PWID behavior.
With sufficient (economic) evidence supporting the
continued operation of Insite, Andresen and Jozaghi [14]
posed another crucial question: should Insite be expanded
in the Downtown Eastside community of Vancouver?
Using a mathematical model to predict the number of
new HIV infections, Andresen and Jozaghi [14] assessed
the viability of expanding the operation of the Insite fa-
cility within Vancouver – both in terms of its individual
operating capacity and the potential for additional SIFs.
They found that although increased hours and extended
service delivery by Insite itself would result in modest
benefits, the addition of further SIFs in other geographic
areas of the city would have a far greater and a more
justifiable economical impact [14]. Specifically, the
benefit-cost ratios supported the expansion of as many
as five additional SIFs.
Related to research on the expansion of SIFs, Jozaghi
et al. [18] conducted a study to assess the economic via-
bility of opening SIFs in the city of Montreal, Quebec,
Canada. Adopting a more comprehensive research design
than the one employed in Andresen and Jozaghi [14], the
authors estimated the number of new HIV and HCV in-
fections that would be prevented with the introduction of
SIFs in Montreal. Accounting for the prevention of each
of these types of harmful diseases, they found that an an-
nual net cost savings of CDN$686 000 (HIV) and CDN
$800 000 (HCV) would be expected for each additional
SIF [18]. Including a variety of SIF operation scenarios to
assess the threshold for diminishing returns, they noted
that the cost saving figures could be expected with expan-
sions that extend to a maximum of three SIFs. See table 1
for a summary of costing studies conducted on SIFs.
In addition to these economic arguments in support of
SIFs, Semaan et al. [28] assess the broader role of SIFs in
reducing HIV and HCV infections as well as overdose
mortality. In this paper, the authors considered ethical,
operational, and public health issues while arguing for
the expansion of SIFs into the United States. With all of
Table 1 Summary of costing studies conducted on SIFs
Study Cost-effectiveness model Variables included Findings
The cost-effectiveness of Vancouver’s
supervised injection facility (Bayoumi
AM, Zaric GS). 2008 [15]
Dynamic compartmental model; 10-
year time horizon
▪ IDUs, non-users, persons with HIV
and HCV, those with
combinations of these states
▪ Over 10-year time horizon, the
introduction of a SIF in Vancouver
would prevent 1191 cases of HIV
and 54 cases of HCV
▪ Sexual transmission, transmission
through needle sharing
▪ Negative net cost of SIF
▪ Population, population shifts ▪ Vancouver SIF would save money
and increase life expectancy
▪ Annual costs
A cost–benefit and cost-effectiveness
analysis of Vancouver’s supervised
injection facility (Andresen MA,
Boyd NT). 2010 [8]
Mathematical modelling ▪ Number of IDUs in population,
number of sharing partners,
participation rate at Insite
▪ Insite has a positive impact on
the health outcomes of IDU
population
▪ Number of needles used per
client-year, number of needles
in circulation, percentage of HIV
infected needles, percentage of
needles not cleaned
▪ Vancouver SIF prevents 35 new
cases of HIV and almost 3 deaths
annually.
▪ Number and rate of shared
injections per year
▪ Provides societal benefit in excess
of $6 million per year after
programme costs are taken into
account
▪ Probability of HIV infection from a
single injection, cumulative
probability of HIV infection, HIV
prevalence rate
▪ Average benefit-cost ratio of 5.12:1
▪ Reduction of risk from
participation
Is Vancouver Canada’s supervised
injection facility cost-saving?
(Pinkerton SD). 2010 [16]
Mathematical modelling
1-year time frame
▪ IDUs living in Vancouver ▪ If Insite were closed, HIV infections
among Vancouver IDU would
increase from 179.3 (1.6% annual
incidence) to 262.8 (2.3% incidence)
▪ Prevalence of HIV infection (%),
annual incidence of HIV
infection (%)
▪ This represents a difference of 83.5
infections per year
▪ Injections per IDU, per year,
injections with borrowed syringes
(%), supervised facility injections,
per year
▪ These preventable infections
would be associated with $17.6
million in life-time HIV-related
medical costs
▪ Syringes distributed in Vancouver,
per year, syringes distributed by
Insite SEP, syringes distributed by
▪ The savings in cost exceeds Insite’s
annual operating costs of
approximately $3 million.
▪ non-Insite sources ▪ Most infections were prevented
thanks to Insite’s syringe exchange
program, which would prevent
80.7 infections
▪ Annual operating cost
(Canadian $)
How many HIV infections are
prevented by Vancouver
Canada’s supervised injection
facility? (Pinkerton SD). 2011 [17]
Mathematical modelling ▪ Number of IDUs ▪ Vancouver SIF prevents
approximately 5–6 infections per
year, with a range of 4–8
prevented infections
▪ HIV prevalence, per injection
transmission rate
▪ Insite SIF reduces HIV incidence
among DTES IDU by 6-11%
▪ Incidence rate without Insite,
incidence reduction
▪ Syringes contaminated with HIV,
decontamination rate
▪ Borrows per IDU per year with
Insite, reduction in number of
borrows
▪ SIF injections per IDU per year
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Table 1 Summary of costing studies conducted on SIFs (Continued)
Potential role of safer injection
facilities in reducing HIV and
Hepatitis C infections and overdose
mortality in the United States
(Semaan S, Fleming P, Worrell C,
Stolp H, Baack B, Miller M).
2011 [28]
Six-factor Kass ethical framework for
public health programs (goals,
effectiveness, concerns,
minimization of concerns, fair
implementation, and balancing of
benefits and concerns)
▪ Public health goals of SIFs and
need for SIFs
▪ SIFs provide settings and public
health interventions that support
safer behaviors and aim to prevent
and reduce HIV, HBV and HCV
infections, infection disparities,
overdose mortality, and injection-
related bacterial infections
▪ Effectiveness of SIFs in achieving
public health goals
▪ SIFs are cost-saving and cost-
effective, prevent accidental
needle-stick injuries in community
members, and reduce public
nuisance and litter
▪ Potential concerns ▪ SIFs provide unique and
complimentary services to other
public health interventions that
promise to improve the health of
PWIDs and the public order and
safety of communities blighted by
public injection
▪ Minimization of concerns and
role of other programs
▪ SIFs provide sterile injection and
drug preparation equipment at
time of injection, a safe and
medically attended environment,
and on-site counseling or referrals
to health and social services,
including addiction treatment and
housing
▪ Fair implementation of important
ethical and contextual factors
that influence the ethical
deliberations and operational
aspects of public health
programs
The point of diminishing returns:
an examination of expanding
Vancouver’s Insite (Andresen MA,
Jozaghi E). 2012 [14]
Mathematical modelling
(Jacobs et al. (1999)
mathematical model)
▪ Expanding Insite’s hours of
operation
▪ Insite operational for 18 hours
predicts that 22 new cases of HIV
are averted annually
▪ Increasing the number of SIFs ▪ Insite is cost-saving. The cost-
benefit ratio is 3.09. The number
of new HIV infections averted, and
the associated cost-savings, are
more than enough to cover
Insite’s annual operating costs
▪ Proportion of IDUs HIV-negative ▪ Insite operational for 24 hours
does not prevent any new HIV
infections
▪ Number of needles in circulation ▪ Expansions of Insite only prevent 1
or 2 additional new cases of HIV
infection▪ Rate of needle-sharing
▪ Percentage of needles not
cleaned
▪ Proportion of IDUs HIV-positive
▪ Probability of HIV infection from
single injection
▪ Number of sharing partners
A cost-benefit/cost-effectiveness
analysis of proposed supervised
injection facilities in Montreal,
Canada (Jozaghi E, Reid AA,
Andresen MA). 2013 [18]
Mathematical modelling using
secondary data
▪ Proportion of IDUs HIV-negative,
proportion of IDUs HIV-positive,
proportion of IDUs HCV-negative,
proportion of IDUs HCV-positive
▪ Increasing scope of SIFs through
site expansion would result in
14–53 fewer HIV and 84–327 fewer
HCV cases annually. The marginal
range would result in 5–14 fewer
HIV and 33–84 fewer HCV cases
annually
▪ Number of needles in circulation,
percentage of needles not
cleaned, rate of needle sharing
▪ Establishing SIFs in Montreal will
benefit the health care system and
expanding SIFs would be a fiscally
responsible course of action
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Table 1 Summary of costing studies conducted on SIFs (Continued)
▪ Probability of HIV infections from
a single injection, probability of
HCV infection from single
injection
▪ With the HIV and HCV cases
averted, SIFs in Montreal would be
cost-saving
▪ Number of sharing partners
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economically viable option for other cities? With respect
to the focus of this study specifically: are SIFs a cost-
effective harm reduction strategy for Ottawa, Ontario
where the rates of HIV and HCV have been estimated to
be higher than those in other major cities in Canada
[21]? Ottawa is of particular interest because, as noted
above, this city is considering the establishment of a SIF
and has issues related to PWIDs that are different from
those in Vancouver.
Data and methods
As shown in Table 2, the data for both the mathematical
models was derived from secondary sources collected
from both published and unpublished studies in 2013.
Of the twelve variables used in the analysis below, six
of them were obtained from research directly related to
the PWID population in Ottawa; the remaining variable
values were obtained from relevant research articles that
have been well-received by researchers in this field.
Modeling a SIF such as Insite must be done with cau-
tion in order to have credible results. Unlike previous
work on Insite – that has considered expansions in
terms of hours of operation and subsequent facilities –
we only consider the establishment of a 24-hour SIF and
its subsequent expansions on both HIV and HCV infec-
tions. We use a 24-hour operation because this has
proved to be a reliable operation framework in some of
our previous research work [14,18]. If the reader wishes
to consider an 18-hour operation, the economic benefitsTable 2 Sources for variables used in mathematical modeling
Variable
Proportion of PWID HIV- (I)
Proportion of PWID HCV- (I)
Rate of Needle sharing (s) or (λ)
Number of needles in circulation (N)
Percentage of needles not cleaned (d)
Probability of HIV infections from a single injection (t) or (α)
Probability of HCV infections from a single injection (t)
Number of sharing partners (m)
Proportion of PWID HIV + (q) or (π)
Proportion of PWID HCV + (q)
Proportion of HIV or HCV infected needles (β)
Probability of needles cleaned (θ)should be multiplied by 0.75. These changes are investi-
gated using the Jacobs et al. [31] and Kaplan and
O’Keefe [5] models, described in detail below; the pri-
mary variable of interest that is influenced by the pres-
ence of a SIF is a modification of the rate of needle
sharing. Because none of the injections within the SIF
are shared injections, its presence decreases the rate of
needle sharing in the PWID population, with the rate of
needle sharing sequentially changing (decreasing) as
more SIFs are added to the mathematical model. How-
ever, these models are static, even when considering
changes in the rate of needle sharing: over time the pres-
ence of a SIF will impact the proportion of PWID that
are HIV + and HCV+. Consequently, with our models
only considering changes in the rate of needle sharing,
our analyses under-estimates the impact of subsequent
SIF expansions.
There are many choices of mathematical models to
use in such an investigation. As discussed above, we
employ the modified versions of the first model (Jacobs
et al. [31]) and the second (Kaplan and O’Keefe [5])
mathematical model of needle exchange programs to
address the changes in the rate of needle sharing, influ-
enced by the establishment of a SIF. The second model
(Kaplan and O’Keefe [5]), and variations thereof, has
been used often in the NEP evaluation literature in
addition to being used in the SIF evaluation literature
[8]. The first model (Jacobs et al. [31]) has been particu-
larly instructive for cost-benefit and cost-effectiveness
analyses in the context of Vancouver’s SIF, Insite, andValue Source
88.00% Bayoumi & Strike [21]; Pilon et al. [29]
39.40% Bayoumi & Strike [21]; Pilon et al. [29]
14% Bayoumi & Strike [21]
837931 City of Ottawa [30]
17.00% Kaplan and O’Keefe [5]; Jacobs et al. [31]
0.67% Kaplan and O’Keefe [5]
3% Gore & Bird [32]
1.38 Jacobs et al. [31]
12.00% Bayoumi & Strike [21]; Pilon et al. [29]
60.60% Bayoumi & Strike [21]; Pilon et al. [29]
40.50% Kaplan and O’Keefe [5]
83% Kaplan and O’Keefe [5]; Jacobs et al. [21]
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over, the first model has been shown to produce estimates
of HIV infection in the PWID population that are very
similar to known data in the Canadian context [14].
Within each of these mathematical models we also employ
behavioural changes in PWID. These behavioural changes
relate to PWID needle sharing behaviour outside of the
SIF. Kerr et al. [13] and Bravo et al. [33] found that PWID
who used the Vancouver SIF also reduced their needle-
sharing activities significantly outside of Insite, with an
odd ratio of 0.30. This has been incorporated into a num-
ber of cost-benefit and cost-effectiveness analyses for SIFs
[8,14,15,18,28]. Because of its widespread use for Insite,
and its empirical evidence [13,33] we incorporate such be-
havioural change for Ottawa in the analyses below.
The first model is estimated as follows:
New HIV=HCV infections ¼ INsd 1− 1−qtð Þm½ 
where I is the proportion of PWID that are HIV- (HCV-),
N is the number of needles in circulation, s is the rate of
needle sharing, d is the percent of needles not cleaned, q is
the proportion of PWID that are HIV + (HCV+), t is the
probability of an HIV (HCV) infection from a single injec-
tion, and m is the average number of sharing partners. It
should be noted that needle cleaning is widely understood
to be partially ineffective, but is retained to keep the model
intact because of its accurate HIV infection estimates, as
stated above. The values for these parameters (and their
sources) are shown in Table 1. In order to estimate the
impact of the SIF on new cases of HIV and HCV infec-
tions, the rate of needle sharing variable is manipulated:
no shared injections are performed within the SIF, and be-
cause of the behavioural change regarding needle sharing,
there are fewer shared injections outside of the SIF, except
in the case of those who are users of the SIF.
The second model is estimated as follows:
New HIV infection rate ¼ 1−πð Þλ 1−θð Þβα
where π is HIV prevalence rate, λ is the rate of needle
sharing, θ is the percentage of needles not cleaned, β
is the percentage of HIV infected needles, and α is the
probability of HIV infection from single injection. As with
the Jacobs et al. [31] mathematical model, the values for
these parameters (and their sources) are shown in Table 2.
And the rate of needle sharing variable is manipulated
in the same manner. Based on research conducted in
Ottawa, our baseline percentage of needle sharing is 14
[21]. However, in the interests of undertaking a sensitivity
analysis – in addition to employing two different mathem-
atical models – we increase and decrease the values of this
variable by 5 percent (19 and 9 percent, respectively) and
recalculate the model results.To ensure reliability, two distinct mathematical
models and a sensitivity analysis were employed. Cost-
effectiveness analysis is one of the main tools of economic
evaluation and the heart of every economic analysis is a
sensitivity analysis. There are a number of assumptions
that are taken into account in every economic analysis,
some of which may not be accurate, thereby introducing
elements of uncertainty. This is especially true when pre-
dicting the cost of a hypothetical program. Therefore, sen-
sitivity analysis and using additional mathematical models
as a secondary form of sensitivity analysis “formalizes
ways to measure and evaluate this uncertainty. Various
researchers have made note of particular sources of un-
certainties that may arise in costing studies [34], p. 297.
In this work, we employ two models and a sensitivity
analysis to account for all sources of uncertainty. Add-
itionally, the behavioural change that impacts the rate
of needle sharing is only applied to the establishment of
the first two SIFs. This is done to generate more conser-
vative results. If the behavioural change is applied in the
same manner to each subsequent SIF established, it can
be implicitly assumed that each SIF attracts a completely
new set of clientele. This is an unrealistic assumption that
we address by only applying the behavioural change twice,
assuming that the existing SIF users will simply use the
greater number of SIFs more frequently.
In order to calculate the economic benefits of reducing
the number of HIV and HCV infections, values for the
costs associated with these infections must be used. The
life-time cost savings made from averted cases of HIV
are at a large magnitude and range from CDN $70,000
to $25000 after considering the very successful multi-
drug combinations Highly Active Antiretroviral Therapy
(HAART) [35-37]. Though the HAART treatments are
highly effective, they are rather intensive and have
low adherence rates within the PWID population [38]—
Laufer [39] has argued that the PWID population is less
likely to take full advantage of the medical system. We
chose to follow the recent research by Pinkerton [16,17],
who used CDN$ 210 555, based on the work of Albert
et al. [25].
With respect to HCV, the most recent costing studies
range from CAN$20,000 to CDN$30,000 [40] to more
than CDN$69,188 [41], per completed patient course of
treatment [42]. In the current analysis, we follow the
National Centre in HIV Epidemiology and Clinical Re-
search [43], using CDN$35,143 (2013 Dollars). We use
this figure for a more conservative estimate regarding
the complications arising from HCV, disregarding the
costs for liver failure, hepatocellular carcinoma and liver
transplant cases.
It is important to note that the calculated cost-savings
of Insite are an under-estimate of the actual cost-
savings. In our analyses, we do not consider any growth
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and HCV infections [44,45], or any reductions in other
harms such as cellulitis, subcutaneous abscesses, endo-
carditis, and other soft-tissue infections [44]. Perhaps,
more significant is the fact that we do not consider the
value of a prevented death. Though the economic bene-
fits are significant, previous research has found that few
deaths are actually prevented from the Vancouver SIF,
Insite [8]. This is also a contentious socio-political issue
that we decided to avoid in the current analysis. Conse-
quently, all cost-savings are more or less an underesti-
mation when we consider the actual cost-savings.
In order to calculate cost-benefit ratios, the total oper-
ational costs of a SIF must be known. We use the cost for
the Vancouver SIF as a proxy: CDN$3 million [16,17,46].
This is the cumulative cost for Insite that includes the SIF,
addiction counselling and case management, the provision
of primary healthcare, public health screening (immunisa-
tions and diagnostics), addiction and housing services,
education, and peer counselling. Andresen and Boyd [8]
list the annual operational cost of the SIF portion of Insite
as CDN$1.5 million, CDN$2.183 million for a 24-hour op-
eration in current dollars [47]. This is the figure that we
use because we are only considering the establishment of
a SIF in Ottawa. We acknowledge that this figure is likely
to be an overestimatation of the total operational costs of
a SIF in Ottawa because a SIF in Ottawa would likely be
smaller in scale than in Vancouver. However, we are un-
aware of any corresponding data that could be used for
such a cost estimate in Ottawa and, as such, the oper-
ational costs used here adds to the conservative nature of
our estimates.
Results and discussion
Results of the current study focus on the cost-benefits
and cost-effectiveness of proposed SIFs in Ottawa, On-
tario. These results are based solely on the prevention of
new HIV and HCV cases, taking into account needle
sharing rates and the PWID behavioural changes that
would occur outside the SIFs. The results presented in
Tables 3 and 4 show that the establishment of SIFs in
Ottawa would result in a decrease in the number of new
HIV and HCV cases. Specifically, the cumulative annual
cost model (Table 3) indicates that 5 to 19 HIV cases
may be averted while 48 to 191 HCV cases may be
averted depending on the number of SIFs established.
The prevention impact of the marginal annual cost
model (Table 4) is not nearly as powerful with ranges
of 2 to 5 and 21 to 48 cases of HIV and HCV being
averted, respectively.
With respect to the fiscal implications of these results,
the decrease in HIV and HCV cases are not enough to
independently cover the cost of SIF operations. In fact,
when considering the operation of the first two SIFs inTables 3 and 4, where behavioural change impacts the
rate of needle sharing, both the cumulative and marginal
cost-benefit ratios are below unity. Specifically, the
cumulative cost-effectiveness for HIV cases (Table 3)
ranges from CDN$436,560 to CDN $804,189 where the
costs associated with a single HIV case is CDN$210,
555. The cumulative cost-effectiveness for HCV (Table 3)
ranges from CDN $45,475 to CDN $79,998 where the
cost of a single HCV case is CDN$35,143. Both of these
ratios are far above the estimated cost per HIV and HCV
case resulting in cost-benefit ratios below 1.0. However,
when the cost-benefit ratios considering both HIV and
HCV are considered simultaneously, there is a financial
justification for at least two SIFs, if not three SIFs with the
last cost-benefit-ratio being 0.95—close enough to 1.0 in
this conservative modeling methodology. This highlights
the importance of considering the additive effects of HIV
and HCV from the establishment of a SIF. In fact, as can
be seen in Table 3, the driver of the cost savings in these
models is HCV, ignored by many of the recent cost evalu-
ations of the Vancouver SIF. However, as indicated before,
owing to the lack of a definitive demonstration of a rela-
tionship in the scientific literature, the result that HCV is
a driving factor in the cost saving must be interpreted with
caution.
Others have also estimated decreases in HCV from
SIFs [21], but this was derived from a mathematical
model.
The independent marginal cost-effectiveness for both HIV
and HCV (Table 4) are also far above the estimated cost per
HIV and HCV case. The marginal cost-effectiveness ranges
from CDN$436,560 to CDN$1,091,400 for HIV and from
CDN$45,475 to CDN$103,943 for HCV. Again, with
costs associated with an HIV case set at CDN$210, 555
and an HCV case set at CDN$35,143, cost-benefit ratios
are below 1.0 and thus, the models do not support
the establishment of SIFs when HIV and HCV are
considered independently. But from a total cost-benefit
perspective, two SIFs can be justified when considering
their marginal impacts on HIV and HCV.
A sensitivity analyses conducted at different baseline
sharing rates (9 and 19 per cent), however, demonstrates
that changes to the needle sharing rates influence the re-
sults in an important way (see Tables 3 to 4). Specifically,
the cumulative (Table 3) and marginal (Table 4) annual
cost models with 9% sharing rates do not support the
establishment of any SIFs as cost-benefit ratios are all
below unity. The cost-effectiveness ratios for HIV and
HCV cases, however, support the establishment of as
many as five (or even six) SIFs when the sharing rate is
set at 19% (see Tables 3 and 4). However, if one were to
only consider HIV or HCV independently, the establish-
ment of a SIF would only be considered as “cost saving”
in the case of HCV, with a maximum of two SIFs. The
Table 3 The cumulative annual cost - effectiveness and benefit-cost of SIF in Ottawa using the first model
Variables Annual cost of
operation
Sharing rate # of HIV
averted
# of HCV
averted
Cost-effectiveness
ratio HCV
Cost-effectiveness
ratio HIV
Benefit-cost ratio
HCV
Benefit-cost ratio
HIV
Cost-benefit ratio
Total
Post SIF $2,182,800 11% 5 48 $45,475 $436,560 0.77 0.48 1.26
(14%, 7%) (6, 3) (65, 31) ($33,581, $70,413) ($363,800, $727,600) (1.1, 0.5) (0.58, 0.3) (1.63, 0.79)
Two SIF $4,365,600 8% 9 88 $49,609 $485,067 0.71 0.43 1.14
(11%, 5%) (12, 6) (120, 57) ($36,380, $76,589) ($383,800, $727,600) (1, 0.46) (0.58, 0.3) (1.54, 0.75)
Three SIF $6,548,400 6% 11 112 $58,468 $595,309 0.6 0.35 0.95
(9%, 4%) (15, 7) (148, 70) ($44,246, $93,549) ($436,560, $936,486) (0.8, 0.38) (0.48, 0.22) (1.28, 0.6)
Four SIF $8,731,200 5% 13 129 $67,683 $671,631 0.52 0.31 0.83
(7%, 3%) (17, 8) (175, 83) ($49,893, $105,195) ($513,600, $1,091,400) (0.7, 0.33) (0.41, 0.19) (1.11, 0.5)
Five SIF $10,914,000 3% 15 150 $72,760 $727,600 0.48 0.29 0.77
(5%, 2%) (20, 9) (203, 96) ($53,764, $113,688) ($545,700, $1,212,667) (0.65, 0.31) (0.39, 0.17) (1.04, 0.48)
Six SIF $13,096,800 2% 17 170 $77,040 $770,400 0.46 0.27 0.73
(3%, 1%) (23, 10) (232, 110) ($569,426, $119,062) ($569,426, $1,309,680) (0.62, 0.3) (0.37, 0.16) (0.99, 0.46)
Seven SIF $15,279,600 1% 19 191 $79,998 $804,189 0.44 0.26 0.70
(1%, 1%) (26, 12) (259, 123) ($58,995, $124,224) ($587,677, $1,273,300) (0.6, 0.28) (0.36, 0.16) (0.55, 0.45)
Note: The numbers in parentheses represent the results of the sensitivity analysis: (19 per cent sharing rate, 9 percent sharing rate).
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Table 4 The marginal annual cost - effectiveness and benefit-cost of sif in Ottawa using the first model
Variables Annual cost of
operation
Sharing
rate
# of HIV
averted
# of HCV
averted
Cost-effectiveness ratio
HCV
Cost-effectiveness
ratio HIV
Benefit-cost ratio
HCV
Benefit-cost ratio
HIV
Cost-benefit ratio
Total
Post SIF $2,182,800 11% 5 48 $45,475 $436,560 0.77 0.48 1.26
(14%, 7%) (6, 3) (65, 31) (33,581, $70,413) ($363,800, $727,600) (1.1, 0.5) (0.58, 0.3) (1.63, 0.79)
Two SIF $2,182,800 8% 4 41 $53,239 $545,700 0.66 0.39 1.05
(11%, 5%) (6, 3) (55, 26) ($39,687, $83,954) ($363,800, $727,600) (0.89, 0.42) (0.58, 0.3) (1.46, 0.71)
Three
SIF
$2,182,800 6% 2 24 $90,950 $1,091,400 0.39 0.19 0.58
(9%, 4%) (3, 1) (28, 14) ($77,957, $155,914) ($727,600, $2,182,800) (0.45, 0.23) (0.29, 0.1) (0.74, 0.32)
Four SIF $2,182,800 5% 2 17 $128,400 $1,091,400 0.27 0.19 0.47
(7%, 3%) (3, 1) (28, 13) ($77,957, $167,908) ($727,600, $2,182,800) (0.45, 0.21) (0.29, 0.1) (0.74, 0.31)
Five SIF $2,182,800 3% 2 21 $103,943 $1,091,400 0.34 0.19 0.53
(5%, 2%) (3, 1) (28, 13) ($77,957, $167,908) ($727,600, $2,182,800) (0.45, 0.21) (0.29, 0.1) (0.74, 0.31)
Six SIF $2,182,800 2% 2 21 $103,943 $1,091,400 0.34 0.19 0.53
(3%, 1%) (3, 1) (28, 13) ($77,957, $167,908) ($727,600, $2,182,800) (0.45, 0.21) (0.29, 0.1) (0.74, 0.31)
Seven
SIF
$2,182,800 1% 2 21 $103,943 $1,091,400 0.34 0.19 0.53
(1%, 1%) (3, 1) (28, 13) ($77,957, $167,908) ($727,600, $2,182,800) (0.45, 0.21) (0.29, 0.1) (0.74, 0.31)
Note: The numbers in parentheses represent the results of the sensitivity analysis: (30 per cent sharing rate, 10 percent sharing rate).
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supports the establishment of a single SIF with a cost-
benefit ratio of 1.1 for only HCV. However, it accounts
for two SIFs when considering the additive impact of
HIV and HCV. Given that the baseline sharing rate of
14% used here is likely to be an underestimation, it can
be argued that the establishment of SIFs should be given
serious considerationa.
Finally, Tables 5 present results of the cost-effectiveness
and cost-benefit of proposed SIFs using the Kaplan and
O’Keefe [5] model that focuses on prevented HIV cases.
As is evident from this table, the number of HIV cases
prevented is not enough to cover the cost of operating a
SIF. Moreover, the cumulative and marginal cost-benefit
ratios are below 1.0 in all SIF scenarios. The same may
be said for the marginal and cumulative cost-effectiveness
ratios.
Conclusions
Several studies have demonstrated the fiscal advantages
of operating Insite – North America’s only legal SIF
[8,14-17]. Research into the economic viability of expand-
ing SIFs to other locations, however, is still in its infancy.
The current study was aimed at contributing to that
growing body of literature, by conducting cost-benefit
and cost-effectiveness analyses for the opening of SIFs
in Ottawa, Ontario. Specifically, the costs of operating
various numbers of SIFs in Ottawa was compared to the
savings incurred after accounting for the prevention of
new HIV and HCV infections.
Results of this study revealed that according to several
analyses, there is an economic incentive to operating SIFs
in Ottawa only if both HIV and HCV are considered. This
is of importance because the specific PWID characteristicsTable 5 The Cumulative and Marginal Cost - Effectiveness and
Variables Annual cost of operation Sharing rate #of HIV
Post SIF $2,182,800 11% 7
($2,182,800) (7
Two SIF $4,365,600 8% 1
($2,182,800) (6
Three SIF $6,548,400 6% 1
($2,182,800) (3
Four SIF $8,731,200 5% 1
($2,182,800) (2
Five SIF $10,914,000 3% 2
($2,182,800) (3
Six SIF $13,096,800 2% 2
($2,182,800) (3
Seven SIF $15,279,600 1% 2
($2,182,800) (3
Note: The numbers in parentheses represent the marginal results.vary in different areas. As a result of this, different base
rates of HIV and HCV infection are likely to determine
whether SIFs are cost-effective or not. The independent
analyses of HIV and HCV, for their cumulative and mar-
ginal annual cost analyses, using the Jacob’s et al. [31]
model both revealed a maximum cost-benefit ratio of 0.48
for HIV cases and 0.77 for HCV cases. Although a slight
improvement over those results, the Kaplan and O’Keefe
[5] cumulative and marginal annual cost models also fell
short of positive results with a cost-benefit ratio of 0.68
for HIV cases. Only when both the effects of reduced HIV
and HCV infections were considered, did the establish-
ment of SIFs achieve cost benefits.
The sensitivity analyses conducted with the first model
did, however, reveal the potential for SIFs in Ottawa to
be a fiscally responsible harm reduction strategy for the
prevention of HCV cases – when considered independ-
ently. With a baseline sharing rate of 19%, the cumula-
tive annual cost model supported the establishment of
two SIFs and the marginal annual cost model supported
the establishment of a single SIF. The cumulative annual
cost model that considered both HIV and HCV, how-
ever, could justify as many as six SIFs while the marginal
annual cost model supported the establishment of two
SIFs. Though these results rely on a needle sharing rate
that is higher than the conservative baseline rate used in
the other analyses, serious consideration should be given
to the establishment of SIFs in Ottawa; especially since
other studies have demonstrated that the 14% baseline
rate is an underestimated rate of needle sharing in the
city rather than overestimated one.
These results also demonstrate the need to routinely
collect accurate, up-to-date, and geographically specific
data so that studies such as this may help to informCost – Benefit of SIF in Ottawa Using the Second Model
averted Cost-effectiveness ratio HIV Benefit-cost ratio HIV
$311,829 0.68
) ($311,829) (0.68)
3 $335,815 0.63
) ($363,800) (0.6)
6 $409,275 0.51
) ($727,600) (0.3)
8 $485,067 0.43
) ($1,091,400) (0.19)
1 $519,714 0.4
) ($727,600) (0.3)
4 $545,700 0.38
) ($727,600) (0.3)
7 $565,911 0.37
) ($727,600) (0.3)
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over, these results also show the importance of considering
more than one potential benefit in cost-benefit analyses
for public health. Though the cost savings from one
averted HCV case would be considerably lower than that
of an averted HIV case (16.69%), the volume of averted
cases of HCV is able to significantly impact cost savings.
Consequently, if we are to properly assess the impact of
harm reduction strategies on our health care system, we
must be as inclusive as possible regarding potential bene-
fits in order to identify all possible savings. In moving for-
ward, research should also consider how to facilitate the
implementation of new SIFs.
We must emphasize that the largest obstacle to imple-
menting a SIF in Ottawa is strong opposition from the
local municipal government and police force as well as
the federal government. These factors are likely to pre-
clude the opening of a SIF in Ottawa irrespective of sci-
entific evidence supporting the implementation of this
intervention. The local health officials, not the federal or
provincial government, should make decisions regarding
opening SIFs, based on the positive impact of SIFs in re-
ducing injections in public, while lowering the overdose
fatalities and infectious diseases [8-11]. SIFs have not in-
creased crime, drug dealing, public injection, public syr-
inge disposal, neither have they contributed to disturbing
public order [48-50]. Accordingly, “concerns that arise out
of prejudice and ignorance for which there are no sound
arguments should be set aside” [51], p. 1304. This will
ultimately help in conceptualizing the injection drug use
as a public health issue, rather than a moral one.
Endnote
aThe baseline sharing rate of 14% is deemed likely to
be an underestimate given that some studies have found
much higher rates of needle sharing in Ottawa. In Leonard
et al. [52], for example, 37% of female PWID and 31% of
male PWID’s reported injecting with previously used nee-
dles within the previous six months. In Leonard et al. [53],
27% of female and 19% of male PWID reported that they
had indulged in using shared needles in the previous six
months. For the current study, however, the most conser-
vative (under-) estimate of needle sharing is used as a
baseline value (14%).
Abbreviations
HCV: Hepatitis C; PWID: People who Inject drugs; SIF: Supervised injection
facility; HIV: Human immunodeficiency virus.
Competing interests
There are no competing interests to report.
Authors’ contributions
EJ collected the data and conducted the analysis, AAR wrote the result,
discussion and conclusion and references, MAA wrote the related studies
section, methods and reviewed the analysis, and AJ wrote the introduction
and references. All authors read and approved the final version of the paper.Received: 22 February 2014 Accepted: 28 July 2014
Published: 4 August 2014
References
1. Mathers BM, Degenhardt L, Buccello C, Lemon J, Wiessing L, Hickman M:
Mortality among people who inject drugs: a systematic review and
meta-analysis. Bull World Health Organ 2013, 91:102–123.
2. World Health Organization: HIV/AIDS: Injecting drug use. 2013,
http://www.who.int/hiv/topics/idu/en/index.html.
3. Rehm J, Ballunas D, Brochu S, Fischer B, Gnam W, Patra J, Popova S,
Sarnocinska-Hart A, Taylor B: The Costs of Substance Abuse in Canada 2002:
Highlights. Ottawa, ON: Canadian Centre on Substance Abuse; 2006.
4. Jozaghi E, Reid, AA: A Case Study of the Transformative Effect of Peer Injection
Drug Users in the Downtown Eastside of Vancouver, Canada. Journal of
Criminology and Criminal Justice 2014, in Press. doi:10.3138/cjccj.2013.E30.
5. Kaplan EH, O’Keefe E: Let the needles do the talking! Evaluating the New
Haven needle exchange. Interfaces 1993, 23:7–26.
6. Gold M, Gafni A, Nelligan P, Millson P: Needle exchange programs: An
economic evaluation of a local experience. Can Med Ass J 1997,
157(3):255–262.
7. Laufer FN: Cost-effectiveness of syringe exchange as an HIV prevention
strategy. J Acquir Immune Defic Syndr 2001, 28:273–278.
8. Andresen MA, Boyd NT: A cost–benefit and cost-effectiveness analysis of
Vancouver’s supervised injection facility. Int J Drug Policy 2010, 21:70–76.
9. Marshall BDL, Milloy M-J, Wood E, Montaner JSG, Kerr T: Reduction in
overdose mortality after the opening of North America’s first medically
supervised safer injecting facility: a retrospective population-based
study. Lancet 2011, 377:1429–1437.
10. Kerr T, Small W, Moore D, Wood E: A micro-environmental intervention to
reduce the harms associated with drug-related overdose: Evidence from
the evaluation of Vancouver’s safer injection facility. Int J Drug Policy
2007, 18:37–45.
11. Wood E, Tyndall MW, Li K, Lioyd-Smith E, Small W, Montaner JSG, Kerr T: Do
supervised injection facilities attract higher-risk injection drug users? Am
J of Prevent Med 2005, 29(2):126–130.
12. Kerr T, Wood E, Palepu A, Wilson D, Schechter MT, Tyndall MW: Responding
to an explosive HIV epidemic driven by frequent cocaine injection: Is
there a role for safe injection facilities? J Drug Issues 2003, 33:579–608.
13. Kerr T, Tyndall M, Li K, Montaner J, Wood E: Safer injection facility use and
syringe sharing in injection drug users. Lancet 2005, 366:316–318.
14. Andresen MA, Jozaghi E: The point of diminishing returns: an examination
of expanding Vancouver’s Insite. Urban Stud 2012, 49(16):3531–3544.
15. Bayoumi AM, Zaric GS: The cost-effectiveness of Vancouver’s supervised
injection facility. Can Med Assoc J 2008, 179(11):1143–1151.
16. Pinkerton SD: Is Vancouver Canada’s supervised injection facility
cost-saving? Addiction 2010, 105:1429–1436.
17. Pinkerton SD: How many HIV infections are prevented by Vancouver
Canada’s supervised injection facility? Int J Drug Policy 2011, 22:179–183.
18. Jozaghi E, Reid AA, Andresen MA: A cost-benefit/cost-effectiveness
analysis of proposed supervised injection facilities in Montreal, Canada.
Subst Abuse Treat Pr 2013, 8(1):25–32.
19. Jozaghi E, Andresen MA: Should North America’s first and only supervised
injection facility (InSite) be expanded in British Columbia, Canada? Harm
Red J 2013, 10(1):1–9.
20. Millson P, Leonard L, Remis RS, Strike C, Challacombe L: Injection Drug Use,
HIV and HCV Infection in Ontario: The Evidence 1992 to 2004. Toronto, ON:
Ontario Ministry of Health and Long-Term Care; 2004.
21. Bayoumi AM, Strike C: Report of the Toronto and Ottawa supervised
consumption assessment study. St. Michael’s Hospital: 2012. Available from:
http://www.stmichaelshospital.com/pdf/research/SMH-TOSCA-report.pdf.
22. Leonard L, DeRubeis E, Strike C: Needs assessment for a safer injecting facility
in Ottawa, Canada. Ottawa, ON: University of Ottawa; 2008.
23. Mills C: Protesters rally at Hill to call for supervised injection site in
Ottawa. Ottawa Citizen 2014. Accessed, March 12, 2014 from http://
ottawacitizen.com/news/protesters-rally-at-hill-to-call-for-supervised-
injection-site-in-ottawa.
24. CSCS Ottawa: Campaign for safer consumption sites in Ottawa. 2014.
Accessed, March 12, 2014 from http://cscsottawa.ca/faits.
25. Albert T, Williams G, Legowski B, Remis R: The Economic Burden of HIV/AIDS
in Canada (CPRN Study Number H-02). Canadian Policy Research Networks:
Ottawa, ON; 1998.
Jozaghi et al. Substance Abuse Treatment, Prevention, and Policy 2014, 9:31 Page 13 of 13
http://www.substanceabusepolicy.com/content/9/1/3126. Des Jarlais DC, Arasteh K, Hagan H: Evaluating Vancouver’s supervised
injection facility: Data and dollars, symbols and ethics. Can Med Assoc J
2008, 179:1105–1106.
27. Kaplan EH: Economic analysis of needle exchange. AIDS 1995,
9:1113–1119.
28. Semaan S, Fleming P, Worrell C, Stolp H, Baack B, Miller M: Potential role of
safer injection facilities in reducing HIV and Hepatitis C infections and
overdoese mortality in the United States. Drug Alc Dep 2011, 118:100–110.
29. Pilon R, Leonard L, Kim J, Vallee D, De Rubeis E, Jolly AM, Wylie J, Pelude L,
Sandstrom P: Transmission patterns of HIV and Hepatitis C virus among
networks of people who inject drugs. PLoS One 2011, 6(7):1–7.
30. City of Ottawa: What is being done about discarded needles in our
communities?. Accessed October 15, 2013 from: http://ottawa.ca/en/
residents/public-health/healthy-living/what-being-done-about-discarded-
needles-our-communities.
31. Jacobs P, Calder P, Taylor M, Houston S, Saunders LD, Albert T: Cost
effectiveness of Streetworks’ needle exchange program of Edmonton.
C J Public Health 1999, 90:168–171.
32. Gore SM, Bird AG: Study size and documentation to detect injection
related hepatitis C in prison. Quantitative J Med 1998, 91:353–357.
33. Bravo MJ, Royuela L, De la Fuente L, Brugal MT, Barrio G, Domingo-Salvany
A, the Itinere Project Group: Use of supervised injection facilities and
injection risk behaviours among young drug injectors. Addiction 2009,
104:614–619.
34. Jain R, Grabner M, Onukwugha E: Sensitivity analysis in cost-effectiveness
studies. Pharmacoeconomics 2011, 29(4):297–314.
35. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA, Stone
BK, Carter J, Call S, Pisu M, Allison J, Saag MS: Distribution of health care
expenditures for HIV-infected patients. Clin Infect Dis 2006, 42:1003–1010.
36. Holtgrave DR, Pinkerton SD: Updates of cost of illness and quality of life
estimates for use in economic evaluations of HIV prevention programs.
JAIDS 1997, 16(1):54–62.
37. Pinkerton SD, Holtgrave DR: A method for evaluating the economic
efficiency of HIV behavioral risk reduction interventions. AIDS Behav 1998,
2(3):189–201.
38. Lert F, Kazatchkine MD: Antiretroviral HIV treatment and care for injecting
drug users: an evidence-based overview. Int J Drug Policy 2007,
18:255–261.
39. Laufer FN: Cost-effectiveness of syringe exchanges as an HIV prevention
strategy. JAIDS 2001, 28:273–278.
40. Werb D, Wood E, Kerr T, Hershfield N, Palmer RWH, Remis RS: Treatment
costs of hepatitis C infection among injection drug users in Canada,
2006–2026. Int J Drug Policy 2011, 22:70–76.
41. Martin N, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ,
Hickman M: Cost-effectiveness of Hepatitis C virus antiviral treatment for
injection drug user populations. Hepatology 2012, 55(1):49–57.
42. Krajden M, Kuo M, Zagorski B, Alvarez M, Yu A, Krahn M: Health care costs
associated with hepatitis C: A longitudinal cohort study. Can J
Gastroenterol 2010, 24(12):717–726.
43. National Centre in HIV Epidemiology and Clinical Research: Epidemiological
and economical impact of potential increased hepatitis C treatment uptake in
Australia. Sydney: The University of New South Wales; 2010.
44. Lurie P, Drucker E: An opportunity lost: HIV infections associated with a
lack of a national needle-exchange programme in the USA. Lancet 1997,
349:604–608.
45. Marshall BD, Wood E, Zhang R, Tyndall MW, Montaner JSG, Kerr T: Condom
use among injection drug users accessing a supervised injection facility.
Sex Transm Infect 2009, 85:121–126.
46. Health Canada: Vancouver’s INSITE service and other Supervised injection sites:
What has been learned from research?. Ottawa, Canada: Final report of the
Expert Advisory Committee; 2008. Available from: http://www.hc-sc.gc.ca/
ahc-asc/pubs/_sites-lieux/insite/index-eng.php.
47. News CTV: Experts table findings on drug-injection site. Vancouver Canada:
2008. Available from: http://www.ctvnews.ca/experts-table-findings-on-drug-
injection-site-1.288775.
48. Hathaway AD, Tousaw KI: Harm reduction headway and continuing
resistance: Insights from safe injection in the city of Vancouver. The Int J
Drug Pol 2008, 19:11–16.
49. Drucker E: Insite: Canada’s landmark safe injecting program at risk. Harm
Red J 2006, 3(24):1–3.50. Stoltz J-A, Wood E, Small W, Li K, Tyndall MW, Montaner JSG, Kerr T:
Changes in injecting practices associated with the use of a medically
supervised safer injection facility. J of Pub Heal 2007, 29(1):35–39.
51. Zlotorzynska M, Wood E, Montaner JS, Kerr T: Supervised injection sites:
Prejudice should not trump evidence of benefit. CMAJ 2013,
185(15):1303–1304.
52. Leonard L, Navarro C, Birkett N: A gendered analysis of injection practices and
sexual behaviours associated with high levels of HIV infection among injection
drug users in the city of Ottawa 1996–2003 update: Issues for HIV prevention
programming and policy development. University of Ottawa: Department of
Epidemiology and Community Medicine; 2004.
53. Leonard L, Navarro C, Birkett N, Remis RS, The POINT Project: Department of
Epidemiology and Community Medicine. University of Ottawa: Faculty of
Medicine; 2005.
doi:10.1186/1747-597X-9-31
Cite this article as: Jozaghi et al.: A cost-benefit/cost-effectiveness
analysis of proposed supervised injection facilities in Ottawa, Canada.
Substance Abuse Treatment, Prevention, and Policy 2014 9:31.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
